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Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia
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Department of Radiology, Faculty of Medicine, Kyoto University, 54-Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-01, Japan.
Summary TNP-470, a synthetic analogue of fumagillin first isolated from Aspergillusfumigatus, is known to
be a potent anti-angiogenic compound. The combined effects on tumour growth and tumour angiogenesis of
TNP-470 and hyperthermia were investigated. The tumour used was SCCVII carcinoma of the C3H/He mouse.
The tumour response was evaluated by the tumour growth (TG) time assay. The TG time is the time required
for one-half of the treated tumours to reach three times the initial tumour volume. Significant delay of tumour
growth was observed by TNP-470 alone (100 mg kg-1 x 2 or x4), indicating that TNP-470 alone has anti-
tumour effect in vivo. When TNP-470 (100 mg kg-
1 x 2 or x 4) was administered after hyperthermia at 44°C,
the TG times of the combined treatment were significantly longer than those of heat alone (44°C) or TNP-470
(100 mg kg-I x 2 or x 4) alone. However, the TG time of combined treatment with TNP-470 and
hyperthermia at 42°C was quite similar to that ofTNP-470 alone. This conflicting result on the combined effect
of TNP-470 and hyperthermia may be related to the temperature-dependent vascular damage by hyperthermia.
Dose-dependent inhibition of angiogenesis by TNP-470 was demonstrated in microangiograms obtained 4 days
and 7 days after hyperthermia (44°C for 30 min). It is, thus, suggested that the combined effect of TNP-470
and hyperthermia is attributable to the inhibition of angiogenesis by TNP-470 following heat-induced vascular
damage.
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Angiogenesis is critical for the growth of solid tumours and
metastasis (Folkman, 1990). Therefore, anti-angiogenic
therapy is probably one of the most promising strategies
for restricting tumour growth (Denekamp, 1991; Bricknell
and Harris, 1991; Brem and Folkman, 1993). TNP-470, a
synthetic analogue of fumagillin first isolated from Aspergil-
lus fumigatus, is known to be a potent anti-angiogenic
compound (Ingber et al., 1990; Kusaka et al., 1991). It has
been found to suppress not only endothelial cell growth in
vitro, but also tumour growth in vivo (Brem and Folkman,
1993; Ingber et al., 1990; Kusaka et al., 1991, 1994; Toi et al.,
1994; Yanase et al., 1993; Yamaoka et al., 1993a,b). The anti-
tumour effect in vivo was thought to be due to inhibition of
angiogenesis.
Blood perfusion plays an important role in the tissue
damage by hyperthermia. Tissue temperature is dependent on
blood flow rate, and it also controls the intratumoral
microenvironment, which affects the thermosensitivity of the
tissue (Song, 1984; Reinhold and Endrich, 1986; Vaupel,
1988). In addition, hyperthermia itself selectively destroys the
tumour vasculature at a high heat dose (Song, 1984;
Reinhold and Endrich, 1986; Vaupel, 1988; Nishimura et
al., 1988a,b). In previous studies, we demonstrated that
heating at 44°C for 30 min almost destroys murine tumour
vasculature and angiogenesis occurs from the peripheral zone
of the tumour 3 days after heating (Nishimura et al., 1988a).
Therefore, it is an interesting question whether inhibition of
the angiogenesis by an angiogenesis inhibitor may enhance
the effect of hyperthermia.
In the present study, we examined the effects of TNP-470
on hyperthermia-induced growth delay of SCCVII tumours.
The effect of TNP-470 on tumour angiogenesis after
hyperthermia was investigated quantitatively by using
microangiography.
Materials and methods
Animal tumour
Eight-week old C3H/He male mice were used throughout the
study. The mice were obtained from Shizuoka Laboratory
Animal Center (Shizuoka, Japan), and kept in our micro-
organism-free animal facility. They were provided with
sterilised mouse pellets and water ad libitum.
SCCVII carcinoma of the C3H/He mice was used. The
SCCVII tumour is a squamous carcinoma that arises
spontaneously in the abdominal wall of a C3H mouse
(Hirst et al., 1982). The SCCVII tumour cell line was
thawed from original frozen stocks and maintained by
alternate passage in syngeneic mice and cell culture in
Eagle's minimum essential medium supplemented with
12.5% fetal bovine serum. Some of the biological character-
istics of the SCCVII tumour were described elsewhere (Hirst
et al., 1982). Approximately 1 x 105 SCCVII tumour cells
collected from monolayer cultures were inoculated s.c. into
the right thigh of the C3H/He male mice both for tumour
growth (TG) time assay and for microangiography. Experi-
ments were performed when the tumours reached 8-10 mm
in diameter.
Drug
TNP-470 was kindly provided by Takeda Chemical
Industries, Osaka, Japan. TNP-470 was dissolved in 5%
arabic gum-saline solution. For the TG time assay, two or
four doses of TNP-470 (100 mg kg-') were administered s.c.
into the back of the mice.When TNP-470 was administered in
combination with hyperthermia, the first dose was given 3 h
after heat treatment (day 0). Second, third and fourth doses
were administered on days 3, 7 and 10 respectively. For
analysis of tumour angiogenesis by microangiography, two
doses of TNP-470 (50 mg kg-' or 100 mg kg-1) were
administered s.c. 3 h after hyperthermia (44°C for 30 min)
and on day 3.
Hyperthermia
Hyperthermia was achieved by immersing the animal's foot
in a water bath. Intratumoral thermometry data have been
described elsewhere (Nishimura et al., 1988a). Generally,
temperatures of thigh tumours were equilibrated within 3-4
min after immersion in the water bath, and remained 0.2-
0.3°C below the water bath temperature. Mice were
anaesthetised before hyperthermia by i.p. injection of
pentobarbital (60 mg kg-'), and the right tumour-bearing
leg was pulled down by a sinker to the water bath. The mice
were air-cooled during the heat treatment. All temperatures
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In this study, two heat doses of 42°C for 30 min and 44°C for
30 min were used.
Assays of tumour response
The tumour response was evaluated by the tumour growth
(TG) time assay. The TG time assay measures the time
required for a tumour to reach 3-fold initial tumour volume
from the first day of treatment. Three diameters of a tumour,
a, b and c were measured using a calliper every 2 days after
various treatments, and the volume was calculated by a
formula; rabc/6. Tumour volume was measured until the
tumour reached 2000 mm3. The TG time was determined for
individual tumours, and the median TG time with 95%
confidence limits (CLs) was calculated for each treatment
group by logit analysis based on the relationship between the
cumulative percentage of tumours that reached 3-fold initial
tumour volume and the days after treatment (Nishimura and
Urano, 1993). Each treatment group consisted of 10-12
mice. Statistical analysis between the treatment groups was
performed using Student's t-test, and P< 0.05 was regarded
as significant difference.
Analysis of tumour angiogenesis
Vascular damage and angiogenesis after hyperthermia were
evaluated by microangiography and correlative histological
sections. The technique of microangiography was described
previously (Nishimura et al., 1988a). Briefly, a filtered barium
sulphate solution (0.25 g ml-') was injected at a pressure of
150 mmHg after flushing the circulatory system with warmed
heparinised saline. When the muscular vasculature of the
hind limb was not opacified sufficiently, the mouse was
excluded from the study to avoid a poor filling artifact. In the
present study, 2 of 42 mice used for microangiography were
excluded from the analysis because of the poor filling artifact.
After the tumour was fixed with 10% buffered formalin,
contact radiographs of 1-mm-thick tumour slices were
obtained. The tumour slice was cut along a sagittal direction
through its centre with as much surrounding normal tissue as
posssible. Correlative histological sections 4 Mm thick were
prepared for each tumour slice and stained with haematox-
ylin and eosin.
Microangiographic changes were analysed quantitatively
as follows (Nishimura et al., 1988a,b). Opacified vascularised
areas and avascular areas in a tumour were demarcated on an
enlarged microangiogram (approximately x 10), and the
vascularised areas (V) and the entire tumour area (T) were
measured using a digital planimeter. Thereafter, the
percentage of vascularised area was calculated as V/T x 100
in each microangiogram. The mean and s.e. of the percentage
ofvascularised area was obtained for each group. Each group
consisted of 4-9 angiograms (mean 6).
Results
TG time assay
The results of TG time assay for TNP-470 are shown in
Table I. The TG times of control tumours and those treated
with TNP-470 (100 mg kg-1x 2) were 7.3 days (95% CL:
6.6-8.0 days) and 8.7 days (8.3-9.2 days) respectively. The
difference between these two TG times was statistically
significant (P<0.05), indicating that TNP-470 alone has an
anti-tumour effect in vivo. When four doses of TNP-470 were
administered, the TG time was further increased.
Figures 1 and 2 show the tumour growth curves for
tumours treated with hyperthermia at 42°C and 44°C with or
without TNP-470 (100 mg kg-' x 2). Hyperthermia alone at
42°C did not result in any growth delay compared with
control tumours, while hyperthermia at 44°C resulted in
significant growth delay compared with untreated control
tumours (P<0.05). When TNP-470 was administered
following hyperthermia at 42°C, the tumour growth curve
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Table I TG time assay of TNP-470 and hyperthermia, SCCVII
tumour
Treatment n TG time (days) (95% CL)
Control 10 7.3 (6.6-8.0)
TNP-470 (100 mg kg-1 x 2) 10 8.7 (8.3-9.2)
TNP-470 (100 mg kg-l x 4) 10 11.8 (10.8-12.9)
HT alone (42°C) 10 6.6 (6.1-7.1)
HT (42°C)+TNP-470
(100 mg kg-x2) 11 8.9 (8.4-9.5)
HT alone (44°C) 11 8.6 (8.0-9.3)
HT (44°C) +TNP-470
(100 mg kg-' x2) 11 10.4 (9.9-10.8)
HT (440C) +TNP-470
(100 mg kg-l x4) 11 16.4 (14.9-18.1)
HT, hyperthermia, heating time was 30 min; n=number ofmice.
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Figure 1 Tumour growth curves for SCCVII tumours treated
with hyperthermia (42°C for 30 min) with or without TNP-470
(100 mgkg- x 2); control tumours (0), hyperthermia alone (El),
TNP-470 alone (@), hyperthermia plus TNP-470 (U). Hyperther-
mia was applied on day 0, and arrows indicate the date of
administration of TNP-470. Vertical bars = s.e.
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Figure 2 Tumour growth curves for SCCVII tumours treated
with hyperthermia (44°C for 30 min) with or without TNP-470
(100 mgkg- x2); control tumours (0), hyperthermia alone (El),
TNP-470 alone (0), hyperthermia plus TNP-470 (U). Hyperther-
mia was applied on day 0, and arrows indicate the date of
administration of TNP-470. Vertical bars=s.e.
was not different from the growth curve for tumours treated
with TNP-470 alone (Figure 1). However, when TNP-470
was administered after hyperthermia at 44°C, significant
tumour growth delay was observed compared with those for
each treatment alone (Figure 2). The TG time of heat at 44°C
and TNP-470 (100 mg kg-' x 2) was significantly longer than
those of heat alone at 44°C or TNP-470 (100 mg kg-' x 2)
alone (P < 0.01). Interestingly, tumour growth curves of
hyperthermia combined with TNP-470 became parallel to
8Hyperthermia and angiogenesis inhibitor
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that of control tumours several days after the last dose of
TNP-470, indicating that the growth delay was closely related
to the administration of TNP-470.
Figure 3 shows the tumour growth curves for tumours
treated with hyperthermia at 44°C with or without TNP-470
(100 mg kg- x 4). Although administration of four doses of
TNP-470 caused apparent suppression of the tumour growth
compared with untreated control tumours, tumour growth
was not inhibited completely. On the other hand, when TNP-
470 was administered following hyperthermia at 44°C,
complete inhibition of tumour growth was observed for 6
days after hyperthermia. The median TG time of the
combination was 16.4 days (14.9-18.1 days), which was
significantly longer than those of TNP-470 alone (100
mg kg-1 x 4) or hyperthermia alone at 44°C (P<0.001).
Tumour angiogenesis
Figure 4 shows the changes in percentage of vascularised area
after heating at 44°C for 30 min. In the previous study,
percentage of vascularised area of untreated SCCVII
carcinoma was 100+ 0%, and no focal avascular area or
necrotic area was observed histologically for untreated
SCCVII tumours (Nishimura et al., 1988a). The percentage
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(Figure Sa). The percentage of vascularised area increased
rapidly at day 4 and day 7 for tumours treated with
hyperthermia alone. In the microangiograms, tapering
capillary sprouts indicating angiogenesis were observed at
the inner edge of the opacified vascularised area (Figure 5b).
For tumours treated with TNP-470 (50 mg kg-1 or 100
mg kg-') following hyperthermia, the percentage of vascu-
larised area increased more slowly than tumours treated with
hyperthermia alone (Figures 4 and 5). Although complete
inhibition of angiogenesis was not observed even when 100
mg kg-' TNP-470 was administered twice weekly, the
percentage of vascularised area of tumours treated with
TNP-470 (100 mg kg-') at day 4 and day 7 were significantly
smaller than those of tumours treated with hyperthermia
alone at day 4 and day 7 (P=0.005 and P=0.018
respectively). The difference in the percentage of vascularised
area at day 4 was borderline significance between TNP-470
(50 mg kg-') and the hyperthermia alone group (P=0.08).
Thus, the rate of tumour angiogenesis was inhibited by TNP-
470 in a dose-dependent manner.
Discussion
ularised area decreased to 6+2% at 1 day after Anti-angiogenic therapy by an angiogenesis inhibitor, TNP-
indicating that tumour vasculature of SCCVII 470, has been studied extensively since Ingber et al. (1990)
na was destroyed nearly completely by the heat dose demonstrated that TNP-470 exhibited inhibitory activity on
endothelial cells and solid tumour growth (Brem and
Folkman, 1993; Kusaka et al., 1991, 1994; Toi et al., 1994;
Yanase et al., 1993; Yamaoka et at., 1993a,b). TNP-470 is
10- one of the synthetic analogues of fumagillin and shows more
potent anti-angiogenic activity and less toxicity than
fumagillin (Kusaka et al., 1991). Kusaka et al. (1994)
demonstrated that TNP-470 inhibited the growth of
endothelial cells in a biphasic manner. The inhibition was
cytostatic in the first phase at a concentration range of 0.3-
3 3000 ng ml-', and it was cytotoxic in the second phase (> 30 ,g ml-1). Because the serum concentration of TNP-470 in
vivo was much lower than that for the cytotoxic inhibition
(Kusaka et al., 1994), TNP-470 should be combined with
other cytotoxic anti-cancer agents in cancer therapy.
Combined effects of TNP-470 and chemotherapy or
1;w ji.,, .,, , . .,................. ,hormone therapy have been demonstrated in several in vivo
0 2 4 6 8 0 12 14 16 18 20 22 24 26 28 studies so far (Yamaoka et al., 1993a,b; Teicher et al., 1994;
Time after treatment (days) Kamei et al., 1993; Toi et al., 1993). In this study, the
3 Tumour growth curves for SCCVII tumours treated combined effects of TNP-470 and hyperthermia were
(perthermia (44°C for 30 min) with or without TNP-470 examined.
gkg x4); control tumours (0), hyperthermia alone (a), Significant growth delay was observed in the TG time
70 alone (0), hyperthermia plus TNP-470 (a). Hyperther- assay by administrating TNP-470 (100 mg kg-') after
iS applied on day 0, and arrows indicate the date of hyperthermia at 44 C compared with either TNP-470 alone
tration of TNP-470. Vertical bars = s.e. or hyperthermia alone (Figures 2 and 3). Blood flow plays the
most important role in the hyperthermic damage in tissues,
including tumours. An important fact is that heat causes
profound changes in tumour vasculature and blood flow 01 (Song, 1984; Reinhold and Endrich, 1986; Vaupel et al, 1988;
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that vascular beds in experimental rodent tumours as well as
those in human tumour xenografts are more vulnerable to
heat compared with those in normal tissues (Song, 1984;
Reinhold and Endrich, 1986). In the previous study, we
demonstrated that heating at 44°C for 30 min destroys
tumour vasculature of the SCCVII tumour nearly completely
and tumour angiogenesis occurs from the peripheral zone of
the tumour 3 days after heating (Nishimura et al., 1988a). On
the other hanci- mlrniqe v2qc-ii1ntiirt wq,, well annnifit-dl either ] _ / 6m, vuivxl iiaiLiu, jluium-u vaa%,uiaLUIls wao Wi-ll VPWIIIV U UILIIV1
o- AC. ~ ., , , , ., ., after hyperthermia alone or hyperthermia combined with
0 1 2 3 4 5 6 7 8 TNP-470 (Figure 5). As TNP-470 has anti-angiogenic activity
against rapidly proliferating endothelium, including tumour
Time after hyperthermia (days) neovascularisation, this drug may have little effect on
physiological states of normal vasculatures except for I Changes in percentage of vascularised area of SCCVII
s following heating at 44°C for 30 min with or without ovulation, menstruation and the development of the placenta
'0: no TNP-470 (v), TNP-470 (50 mgkg-l x 2) (A), (Folkman, 1985). Thus, it is very likely that TNP-470
'0 (100 mgkg-1x2) (0). Hyperthermia was applied on prolonged the growth delay by inhibiting the tumour
and arrows indicate the date of administration of TNP- angiogenesis following hyperthermia.
rtical bars = s.e. As shown in Figures 2 and 3, growth rate of tumoursHyperthermia and angiogenesis inhibitor
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Figure 5 Microangiograms of SCCVII tumours. (a) One day after hyperthermia (44°C for 30 min). Tumour vessels showed nearly
no filling, although muscular vessels were well opacified. (b) Seven days after hyperthermia alone. A small avascular area was
surrounded by extensive angiogenesis. Tapering capillary sprouts were well observed at the inner edge of the opacified vascularised
area. (c) Seven days after hyperthermia treated with TNP-470 (50 mgkg- 1 x 2). Although angiogenesis was also noted, a moderate
avascular area was present. (d) Seven days after hyperthermia treated with TNP-470 (100 mgkg- 1 x 2). A wide avascular area was
still present, indicating inhibition of angiogenesis by TNP-470.
treated with hyperthermia and TNP-470 returned to the
same level as that of control tumours several days after the
last dose of TNP-470. This indicates that the inhibition of
angiogenesis by TNP-470 was cytostatic and endothelial cells
regrew after the cessation of administration of TNP-470.
Such cytostatic inhibition of endothelial cells by TNP-470
and regrowth after removal of the drug was well
demonstrated in vitro (Kusaka et al., 1994).
Although the combined effect of TNP-470 and hyperther-
mia was noted at 44°C heating, it was not demonstrated at
42°C (Figures 1 and 2). Apparently vascular damage by
hyperthermia is temperature dependent (Song, 1984; Rein-
hold and Endrich, 1986; Vaupel, 1988; Nishimura et al.,
1988a). In the previous study, we demonstrated that 95% of
tumour vasculature of the SCCVII tumour was destroyed 24
h after heating at 44°C, whereas only 24% of tumour
vasculature was destroyed 24 h after heating at 42°C
(Nishimura et al., 1988a). Because heat effects are also time
dependent, severe vascular damage may occur when
hyperthermia is applied for longer periods at 42°C. It is
apparent that heat dose is more important than the heating
temperature itself. TNP-470 might have greater effects after a
high heat dose than a low heat dose, because significant
portions of tumour vasculature should be damaged by
hyperthermia before administrating an angiogenesis inhibitor.
In clinical hyperthermia only limited portions of the
tumour volume can be heated to 43-44°C even for
superficial tumours. In addition, the tumour vasculature of
human tumours is considered to be more resistant to heat
than the murine tumour vasculature (Waterman et al., 1987).
Thus, it remains unclear whether this particular combination
between TNP-470 and high temperature hyperthermia will
have clinical relevance. However, CT scans obtained after
clinical thermoradiotherapy showed a clear low-density area
in well-heated human tumours, which was confirmed
histologically to be coagulation necrosis (Hiraoka et al.,
1987; Nishimura et al., 1989). Leopold et al. (1992) reported
that 60% of human soft tissue sarcomas treated with
preoperative thermoradiotherapy showed tumour necrosis
of >80% area in resected specimens. Jo et al. (1989)
demonstrated that small tumour blood vessels and capillaries
in human tumour parenchyma were markedly damaged after
thermoradiotherapy. Thus, it is likely that human tumour
vasculatures may be severely damaged by several sessions of
satisfactory heating combined with radiation therapy.
Therefore, TNP-470 may be clinically useful if it is
combined with thermoradiotherapy of good heating quality.
In the analysis of tumour angiogenesis by microangio-
graphy, significant inhibition of angiogenesis was observed
by TNP-470. Although inhibition of angiogenesis by TNP-
470 has been demonstrated by a vascular grading system in
human nerve sheath tumours (Takamiya et al., 1993), this
study first showed that TNP-470 inhibited tumour angiogen-
esis in vivo quantitatively. This analysis system of tumour
angiogenesis after hyperthermia seems a good model to
study angiogenesis of murine tumour vasculature in vivo
because hyperthermia at a high heat dose inevitably destroys
murine tumour vasculature followed by angiogenesis. The
effect of TNP-470 alone on spontaneously growing tumour
vasculature was not studied in the microangiography because
rapid tumour angiogenesis was not observed in microangio-
grams without initial vascular damage by hyperthermia.
Dose-dependent inhibition of angiogenesis by TNP-470
was clearly demonstrated in Figure 4. However, complete
aHyperthermia and angiogenesis inhibitor
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inhibition of angiogenesis was not observed even when 100
mg kg-' TNP-470 was administered twice weekly. Because
complete inhibition of endothelial cell growth by TNP-470
was noted as low as 0.3 ng ml-' in vitro (Kusaka et al., 1994;
Toi et al., 1994), the concentration of TNP-470 at the tumour
tissue may be less than that level. On the other hand,
complete inhibition of tumour growth by TNP-470 was
observed for 6 days after hyperthermia at 44°C in the TG
time assay (Figure 3), although tumour regrowth started
when third and fourth doses of TNP-470 were still
administered. As shown in Figures 4 and 5, tumour
angiogenesis was progressing slowly by replacing necrotic
area with viable tumour cells even when the tumour volume
was not changed. Thus, changes in tumour volume began to
occur after a substantial portion of necrotic area was
replaced by viable tumour cells. Therefore, it is unlikely
that the tumour endothelial cells become resistant to TNP-
470 after administration of several doses. To obtain complete
inhibition of tumour angiogenesis, administration of TNP-
470 with shorter interval and/or higher doses may be
necessary.
In the present study, TNP-470 was given after hyperther-
mia to investigate its effects on tumour angiogenesis.
However, TNP-470 may enhance heat effects when it is
administered before heating. Inhibition of tumour angiogen-
esis by TNP-470 may make the intratumoral environment
more acidic and hypoxic, which increases the hyperthermic
damage to tissues (Song, 1984; Reinhold and Endrich,
1986;Vaupel, 1988). Further study to confirm this hypothesis
is in progress.
In conclusion, our results indicated that the greater
tumour growth delay produced by the combination of
TNP-470 and hyperthermia at 44°C resulted from the
inhibition of tumour angiogenesis following heat-induced
vascular damage. As hyperthermia is a clinically applicable
vascular-damaging agent, the combination of hyperthermia
and anti-angiogenic treatment seems a promising strategy.
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